BridgeBio Pharma Dirección

Dirección controles de criterios 2/4

El CEO de BridgeBio Pharma's es Neil Kumar , nombrado en Apr 2015, tiene una permanencia de 9.17 años. compensación anual total es $12.16M, compuesta por 6.1% salario y 93.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 3.69% de las acciones de la empresa, por valor de €187.23M. La antigüedad media del equipo directivo y de la junta directiva es de 5.4 años y 4.4 años, respectivamente.

Información clave

Neil Kumar

Chief Executive Officer (CEO)

US$12.2m

Compensación total

Porcentaje del salario del CEO	6.1%
Permanencia del CEO	9.5yrs
Participación del CEO	3.7%
Permanencia media de la dirección	5.3yrs
Promedio de permanencia en la Junta Directiva	4.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Neil Kumar en comparación con los beneficios de BridgeBio Pharma?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-US$454m
Mar 31 2024	n/a	n/a	-US$538m
Dec 31 2023	US$12m	US$742k	-US$643m
Sep 30 2023	n/a	n/a	-US$613m
Jun 30 2023	n/a	n/a	-US$573m
Mar 31 2023	n/a	n/a	-US$425m
Dec 31 2022	US$7m	US$1m	-US$481m
Sep 30 2022	n/a	n/a	-US$491m
Jun 30 2022	n/a	n/a	-US$509m
Mar 31 2022	n/a	n/a	-US$596m
Dec 31 2021	US$26m	US$725k	-US$563m
Sep 30 2021	n/a	n/a	-US$535m
Jun 30 2021	n/a	n/a	-US$495m
Mar 31 2021	n/a	n/a	-US$520m
Dec 31 2020	US$10m	US$550k	-US$449m
Sep 30 2020	n/a	n/a	-US$402m
Jun 30 2020	n/a	n/a	-US$346m
Mar 31 2020	n/a	n/a	-US$291m
Dec 31 2019	US$26m	US$503k	-US$261m
Sep 30 2019	n/a	n/a	-US$226m
Jun 30 2019	n/a	n/a	-US$197m
Mar 31 2019	n/a	n/a	-US$155m
Dec 31 2018	US$450k	US$450k	-US$131m

Compensación vs. Mercado: La compensación total de Neil($USD12.16M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD3.28M).

Compensación vs. Ingresos: La compensación de Neil ha aumentado mientras la empresa no es rentable.

CEO

Neil Kumar (45 yo)

9.5yrs

Permanencia

US$12,158,626

Compensación

Dr. Neil Kumar, Ph D., has been Director of Lianbio since October 2019. He is a Co-Founder of BridgeBio Pharma, Inc. and serves as its Chief Executive Officer and Director since April 2015.He served as Pr...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Neil Kumar	Co-Founder	9.5yrs	US$12.16m	3.67% $ 158.7m
Charles Homcy	Co-Founder	no data	US$1.11m	0.65% $ 28.3m
Frank McCormick	Co-Founder	no data	US$1.74m	0.59% $ 25.3m
Brian Stephenson	CFO & Secretary	6yrs	US$6.65m	0.045% $ 2.0m
Richard Scheller	Chairman of Research & Development	5.8yrs	US$2.01m	sin datos
Thomas Trimarchi	President & COO	less than a year	sin datos	0.20% $ 8.7m
Uma Sinha	Chief Scientific Officer	8.5yrs	US$2.75m	sin datos
Grace Rauh	Vice President of Communications	no data	sin datos	sin datos
Eli Wallace	Chief Scientific Officer of Oncology	4.8yrs	sin datos	sin datos
Eric David	Chief Executive Officer of Gene Therapy	no data	sin datos	sin datos
Matthew Outten	Chief Commercial Officer	3.4yrs	sin datos	sin datos
Adora Ndu	Chief Regulatory Affairs Officer	2.8yrs	sin datos	sin datos

5.3yrs

Permanencia media

54.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 2CL es experimentado (5.4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Neil Kumar	Co-Founder	9.5yrs	US$12.16m	3.67% $ 158.7m
Charles Homcy	Co-Founder	5.9yrs	US$1.11m	0.65% $ 28.3m
Frank McCormick	Co-Founder	less than a year	US$1.74m	0.59% $ 25.3m
Fred Hassan	Independent Director	3.2yrs	US$600.00k	0.010% $ 443.5k
Ronald Daniels	Independent Director	4.7yrs	US$600.00k	0.0055% $ 239.0k
Eric Aguiar	Independent Director	5.6yrs	US$600.00k	0% $ 0
Randal Scott	Independent Director	4.3yrs	US$600.00k	0.0048% $ 207.0k
Ali Satvat	Independent Director	8.6yrs	US$600.00k	0% $ 0
James Momtazee	Director	8.6yrs	US$600.00k	0.047% $ 2.0m
Jennifer Cook	Director	4.8yrs	US$600.00k	0.0038% $ 164.2k
Wen-Chaun Lo	Independent Director	4.3yrs	US$600.00k	0.13% $ 5.8m
Andrea Ellis	Independent Director	3.2yrs	US$600.00k	0.0064% $ 275.8k

4.8yrs

Permanencia media

62.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 2CL se considera experimentada (4.4 años de antigüedad promedio).

BridgeBio Pharma Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

BridgeBio Pharma, Inc. Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer

BridgeBio Pharma, Inc., Annual General Meeting, Jun 21, 2024

BridgeBio Pharma, Inc., Annual General Meeting, Jun 22, 2022

Independent Director recently bought €264k worth of stock

Recent updates

BridgeBio Pharma, Inc. Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

BridgeBio Pharma, Inc. Presents Additional Data from an Analysis of its Phase 3 ATTRibute-CM and Open-Label Extension Study of Acoramidis in ATTR-CM at the European Society of Cardiology 2024

BridgeBio Pharma, Inc. and QED Therapeutics Announce the Launch of the Initial Phase of MyAchonJourney

Second quarter 2024 earnings released: US$0.39 loss per share (vs US$0.98 loss in 2Q 2023)

BridgeBio Pharma, Inc. Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer

BridgeBio Pharma, Inc. Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

BridgeBio Pharma, Inc. Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia

BridgeBio Pharma, Inc., Annual General Meeting, Jun 21, 2024

BridgeBio Pharma, Inc. Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement

BridgeBio Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $250.00001 million.

BridgeBio Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $250.00001 million.

BridgeBio Pharma, Inc. has filed a Follow-on Equity Offering.

Full year 2023 earnings released: US$3.95 loss per share (vs US$3.26 loss in FY 2022)

New major risk - Financial position

BridgeBio Pharma, Inc. Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy

BridgeBio Pharma, Inc. Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months

BridgeBio Pharma, Inc. Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy in the New England Journal of Medicine

BridgeBio Pharma, Inc. Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia

BridgeBio Pharma, Inc. Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

BridgeBio Pharma, Inc. Shares Positive Long-Term Data from an Ongoing Phase 2 Study, Which Support the Potential Use of Glycosylated Alpha-dystroglycan (DG) Levels as a Surrogate Endpoint in Limb-Girdle Muscular Dystrophy Type 2I/R9

BridgeBio Pharma, Inc. announced that it expects to receive $250.003806 million in funding from Qatar Investment Authority and other investors

BridgeBio Pharma, Inc. announced that it expects to receive $250.003806 million in funding from Qatar Investment Authority and other investors

Bridgebio Pharma Announces Positive Feedback from the U.S. Fda and Eu Ema on the Regulatory Path for A Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia

BridgeBio Pharma, Inc. Presents Detailed Positive Results from Phase 3 Attribute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) At European Society of Cardiology Congress 2023

New minor risk - Financial position

Second quarter 2023 earnings released: US$0.98 loss per share (vs US$0.067 loss in 2Q 2022)

Bridgebio Pharma Announces Opportunity for Accelerated Approval Pathway in Limb-Girdle Muscular Dystrophy Type 2I (Lgmd2i/R9) Based on Glycosylated Alpha-Dystroglycan (Dg) Levels and Announces First Patient Dosed in Fortify Phase 3 Study

Bridgebio Announces Consistently Positive Results from Phase 3 Attribute-Cm Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy

BridgeBio Pharma, Inc. Presents Updated Six Month Results from Its Phase 2 Cohort 5 Trial of Infigratinib in Achondroplasia

Full year 2022 earnings released: US$3.26 loss per share (vs US$3.90 loss in FY 2021)

Bridgebio Pharma, Inc. Initiates CALIBRATE, A Pivotal Phase 3 Study of Encaleret in Autosomal Dominant Hypocalcemia Type 1

BridgeBio Pharm and ML Bio Solutions Present 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i)

BridgeBio Pharma, Inc Presents Updated Positive Data from Its BBP-812 Canavan Disease Gene Therapy Program At the 51st Annual Meeting of the Child Neurology Society

BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial and US FDA Fast Track Designation for SHP2 Inhibitor BBP-398 in Combination with Amgen's Lumakras(R) (Sotorasib)

BridgeBio Pharma, Inc. to Present New Data on its Novel Approaches to RAS-driven Cancers at the Fourth RAS Initiative Symposium

BridgeBio Pharma and Sentynl Therapeutics Receive Marketing Authorization in the EU for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A

BridgeBio Pharma, Inc Announces Dosing of First Patient in Phase 1 Trial of BBP-671

BridgeBio Pharma, Sentynl Therapeutics and Medison Pharma Announce Approval in Israel for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A

BridgeBio Pharma, Inc. Announces Positive Interim Results from PROPEL 2

BridgeBio Pharma, Inc. and Sentynl Therapeutics, Inc. Receive Positive CHMP Opinion for NULIBRY® (Fosdenopterin) for Treatment of MoCD Type A

BridgeBio Pharma Announces Positive Phase 1 Data and Phase 2/3 Trial Design for BBP-711, a Potentially Best-In-Class GO Inhibitor for Primary Hyperoxaluria Type 1 (PH1) and Recurrent Kidney Stone Formers

BridgeBio Pharma Announces Early Positive Data for BBP-812, its Investigational AAV9 Gene Therapy for Canavan Disease

BridgeBio Pharma, Inc. Shares Positive Phase 2B Data and Announces Pivotal Study Design for Phase 3 Trial of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1)

BridgeBio Pharma, Inc. and Venthera, Inc. Presents Preliminary Results from Clinical Trial of VT30 (BBP-681) for Venous, Lymphatic, and Venolymphatic Malformations

BridgeBio Pharma Presents Positive Phase 1 Data in Healthy Volunteers, Advancing Development of BBP-671 for Pantothenate Kinase-Associated Neurodegeneration (PKAN) and Organic Acidemias

BridgeBio Pharma, Inc. and Phoenix Tissue Repair, Inc Announce Positive Results from Phase 2 Trial of PTR-01

BridgeBio Pharma, Inc., Annual General Meeting, Jun 22, 2022

BridgeBio Pharma Presents Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Sentynl Therapeutics Inc. entered into an asset purchase agreement to acquire Global Rights to NULIBRY from BridgeBio Pharma, Inc. (NasdaqGS:BBIO).

BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)

Independent Director recently bought €264k worth of stock

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad